Authors


Mark D. Tyson, MD, MPH

Latest:

Nadofaragene firadenovec maintains safety, efficacy in real-world population

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.


Matthew J. Mutter, MD

Latest:

Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy

"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD.


Shay Rajavel, MS3

Latest:

Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy

Shay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.


Northwestern Medicine

Latest:

As Patients Live Longer, New Criteria Needed for Prostate Cancer Trials

Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.


Matthew Fowler

Latest:

Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBC

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.


Shreyas S. Joshi, MD, MPH

Latest:

Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and optimized therapy sequencing to improve outcomes, as current approaches still leave many patients at risk of relapse despite expanding therapeutic options.


Gautam Jayram, MD

Latest:

Gautam Jayram, MD, on key bladder cancer agents to keep an eye on

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.


Courtney Marabella

Latest:

Update offers clues to optimal olaparib use in prostate cancer

The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.


Jad Chahoud, MD, MPH, MHA

Latest:

Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC

The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.


Daniel S. Roberson, MD

Latest:

Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs

“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.


Logan Lutton

Latest:

Coaching program aims to alleviate female physician burnout

Cofounders Adrienne Mann, MD, and Tyra Fainstad, MD, discuss Better Together, a professional, structured coaching program designed to address the burnout experienced by women in medicine.


American Urogynecologic Society

Latest:

Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025

Submit your abstract and/or roundtable and workshop proposal for PFD Week 2025, to be held October 14-17 in Vancouver, Canada!


Nicolette G. Payne, MD

Latest:

Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists

The research identified several risk factors for high burnout, including younger age, female gender, and longer working hours.


Leilei Xia, MD

Latest:

Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs

“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.


Michael Jenson, PA-C

Latest:

Urology PA on how the Surgical Impotence Management Strategy program results in better informed patients

"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.


Darlene Dobkowski, MA

Latest:

Darolutamide linked to fewer hospitalizations in patients with mHSPC

Compared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.


Anthony Brooks, MD

Latest:

Fertility preservation in patients with testicular cancer

"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.


Kelvin Moses, MD, PhD

Latest:

Diversity in Urology: Progress made, but there is more work to be done

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.


Evan Kovac, MD

Latest:

Future Directions for Imaging and Biopsy in Prostate Cancer

The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.


Renee Dowling

Latest:

Everything you need to know about medical coding and billing audits

Through medical claims audits, the practice can help protected itself against fraudulent billing activity and claims.


Nilay Gandhi, MD

Latest:

Overview of Advanced/Metastatic Prostate Cancer

In the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy.


Lauren Hanson

Latest:

Tips for physicians to improve work-life balance

Overworking has become the norm, but that doesn’t mean it should be.


Pharmacy Times Staff

Latest:

Case report details spontaneous bladder rupture caused by herpes zoster–associated urinary retention

Although cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.


Jim Lu, MD, PhD

Latest:

Molecular diagnostic practice in prostate and bladder cancers

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.


Daniel A. Barocas, MD, MPH, FACS

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Michelle Semins, MD

Latest:

Future Perspectives in the Treatment of Patients With Urinary Stones

Drs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.


Dave S. Gilreath, CFP

Latest:

Money Matters: Informing your perspective on the bear market

No matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.


Shane Peng, MD

Latest:

Expert explains challenges of telehealth

Although much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.


Sam S. Chang, MD, MBA

Latest:

Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.


Allen Alishahi

Latest:

Ensuring operational continuity is critical with healthcare data breaches

With healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.

© 2025 MJH Life Sciences

All rights reserved.